Ractigen Therapeutics Publishes Foundational Study on its Extrahepatic LiCO™ Delivery Platform in Molecular Therapy - Nucleic Acids

Peer-reviewed study demonstrates potent, multi-month extrahepatic delivery via both systemic administration—targeting skeletal muscle, heart, and adipose tissue—and localized routes across ocular, joint, and bladder compartments Unlocks high-value therapeutic tissues for neuromuscular,...

Read the full story at Ractigen Therapeutics via PR Newswire (opens in a new tab)

Headline and summary from Ractigen Therapeutics via PR Newswire; the full story is on the publisher's site. Nothing here is investment advice.